{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04497805",
      "OrgStudyIdInfo": {
        "OrgStudyId": "ALLO-ASC-SHEET"
      },
      "Organization": {
        "OrgFullName": "Anterogen Co., Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers",
      "OfficialTitle": "A Phase 2 Clinical Study to Evaluate The Efficacy and Safety of ALLO-ASC-SHEET in the Subjects With Diabetic Wagner Grade II Foot Ulcers"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2021",
      "OverallStatus": "Recruiting",
      "StartDateStruct": {
        "StartDate": "August 1, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "May 15, 2020",
      "StudyFirstSubmitQCDate": "August 3, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "August 4, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 21, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 22, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Anterogen Co., Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a phase 2 double-blind clinical study to evaluate the efficacy and Safety of ALLO-ASC-SHEET in subjects with Diabetic Wagner Grade II Foot Ulcers, compared to placebo therapy."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Diabetic Foot Ulcer"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "64",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "ALLO-ASC-SHEET",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "ALLO-ASC-SHEET Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: ALLO-ASC-SHEET"
              ]
            }
          },
          {
            "ArmGroupLabel": "Hydrogel SHEET(Vehicle control)",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: ALLO-ASC-SHEET"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "ALLO-ASC-SHEET",
            "InterventionDescription": "Hydrogel sheet containing Allogenic Mesenchymal Stem Cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "ALLO-ASC-SHEET",
                "Hydrogel SHEET(Vehicle control)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Hydrogel sheet containing Allogenic Mesenchymal Stem Cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Proportions of subjects who achieved complete wound closure.",
            "PrimaryOutcomeDescription": "Proportions of subjects who achieved complete wound closure during the 12 weeks.",
            "PrimaryOutcomeTimeFrame": "During 12 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Time to initial complete wound closure between the 2 groups.",
            "SecondaryOutcomeDescription": "Measure the time to initial complete wound closure between the 2 groups.",
            "SecondaryOutcomeTimeFrame": "During 12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in wound size compared to baseline between the 2 groups.",
            "SecondaryOutcomeDescription": "Wound size is measured by using eKare 3D Wound Measurement system(Mobile Devices).",
            "SecondaryOutcomeTimeFrame": "During 12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of wound size.",
            "SecondaryOutcomeDescription": "Proportions of subjects who achieved complete wound closure by the classification of wound size, 1.5~7 cm2 and 7.1~15 cm2 between the 2 groups at every visit.",
            "SecondaryOutcomeTimeFrame": "During 12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of location of diabetic foot ulcer.",
            "SecondaryOutcomeDescription": "Proportions of subjects who achieved complete wound closure by the classification of location of diabetic foot ulcer, plantar and dorsal between the 2 groups at every visit by post-hoc analysis.",
            "SecondaryOutcomeTimeFrame": "During 12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Durability of complete wound closure for the additional 24 weeks.",
            "SecondaryOutcomeDescription": "Durability of complete wound closure for the additional 24 weeks from the initial complete wound closure.\n\nWound size is measured by using eKare 3D Wound Measurement system(Mobile Devices).",
            "SecondaryOutcomeTimeFrame": "During 36 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMale or female between 18 and 80 years of age.\nDiagnosed with Type I or Type II diabetes and has Wagner Grade II diabetic foot ulcers for longer than 4 weeks at the time of screening.\nFoot ulcer located in the plantar or dorsal, with ulcer size between1.5 cm2 and 15 cm2.\nUlcer, Graded II by Wagner grade, and extended to muscle periosteum, muscle, tendon, or joint capsule, but not to bone.\nUlcer is free of necrotic debris,exhibits no signs of clinical infection.\n\nUlcer area blood circulation meets 1 of the following criteria:\n\nA. Blood vessels around the ulcer detected by Doppler Test to have biphasic or triphasic flow B. Range of Ankle Brachial Index(ABI) is>0.7 to <1.3 C. Transcutaneous oxygen pressure (TcPO2) >30 mmHg.\n\nIs able to give written informed consent prior to study start and to comply with the study requirements.\n\nExclusion Criteria:\n\nUlcer is of non-diabetic pathophysiology.\nThe ulcer has increased or decreased in size by â‰¥30% during 2 weeks screening period.\nPatient is currently on higher dose antibiotic therapy as defined by increased dose or change in therapy from the initial treatment regimen at screening to treat index wound infection or patient is on suppressive antibiotic therapy for diabetic foot wound infection.\nThe longest dimension of the index wound exceeds 15 cm at the baseline visit.\nPatient with skin lesion confirmed by biopsy (when Investigator deems suspicious) and then judged by Investigator to be an etiology other than diabetic foot ulcer (i.e.,example skin cancer in situ, pyoderma).\nCurrent evidence of active charcot, osteomyelitis, cellulitis, or evidence of other infection including fever or purulentdrainage from wound site.\nIs Human Immunodeficiency Virus (HIV) positive\nHavesevere hepatic deficiencies.\nHave a glycated hemoglobin A1c (HbA1c) level of >10%.\nHave an allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue.\nHave severe renal function insufficiency documented with creatinine greater than 3.0 mg/dL.\nPregnant or breast-feeding.\nIs unwilling to use an \"effective\" method of contraception during the study.\nHave evidence of current infection including purulent drainage from the wound site.\nHave a clinically relevant history of alcohol or drugs abuse.\nHave postprandialblood sugar >350 mg/dL at screening.\nIs not able to comply with the study requirements.\nIs considered by the Investigator to have a significant disease which might impact the study.\nIs considered not suitable for the study by Investigator.\nHave a history of malignancy within the last 5 years (except basal cell carcinoma in situ).\nIs currently or were enrolled in another clinical study within 60 days of screening.\nHave undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days.\nIs receiving oral or parenteral corticosteroids (In doses greater than 10 mg per day), any immunosuppressive, or cytotoxic agents with unstable dose prior to 4 weeks from screening.\nCannot maintain off-loading process.\nPanel reactive antibody (PRA) levels â‰¥ 20% at screening.\nVenereal Disease Research Laboratory test (VDRL) or RPR positive",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Yun Jung Choi, PM",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "82 10 9199 0164",
            "CentralContactEMail": "yunjungchoi@anterogen.com"
          },
          {
            "CentralContactName": "Jessi Choi, PM",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "82 10 9199 0164"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Yun Jung Choi, PM",
            "OverallOfficialAffiliation": "Anterogen Co., Ltd.",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of Southern California",
            "LocationStatus": "Recruiting",
            "LocationCity": "Los Angeles",
            "LocationState": "California",
            "LocationZip": "90033",
            "LocationCountry": "United States",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "David Armstrong, MD",
                  "LocationContactRole": "Contact"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000017719",
            "ConditionMeshTerm": "Diabetic Foot"
          },
          {
            "ConditionMeshId": "D000016523",
            "ConditionMeshTerm": "Foot Ulcer"
          },
          {
            "ConditionMeshId": "D000014456",
            "ConditionMeshTerm": "Ulcer"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000003925",
            "ConditionAncestorTerm": "Diabetic Angiopathies"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000007871",
            "ConditionAncestorTerm": "Leg Ulcer"
          },
          {
            "ConditionAncestorId": "D000012883",
            "ConditionAncestorTerm": "Skin Ulcer"
          },
          {
            "ConditionAncestorId": "D000012871",
            "ConditionAncestorTerm": "Skin Diseases"
          },
          {
            "ConditionAncestorId": "D000048909",
            "ConditionAncestorTerm": "Diabetes Complications"
          },
          {
            "ConditionAncestorId": "D000003920",
            "ConditionAncestorTerm": "Diabetes Mellitus"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          },
          {
            "ConditionAncestorId": "D000003929",
            "ConditionAncestorTerm": "Diabetic Neuropathies"
          },
          {
            "ConditionAncestorId": "D000005534",
            "ConditionAncestorTerm": "Foot Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M16358",
            "ConditionBrowseLeafName": "Ulcer",
            "ConditionBrowseLeafAsFound": "Ulcer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19085",
            "ConditionBrowseLeafName": "Diabetic Foot",
            "ConditionBrowseLeafAsFound": "Diabetic Foot",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M18071",
            "ConditionBrowseLeafName": "Foot Ulcer",
            "ConditionBrowseLeafAsFound": "Foot Ulcers",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6272",
            "ConditionBrowseLeafName": "Diabetic Angiopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10035",
            "ConditionBrowseLeafName": "Leg Ulcer",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14838",
            "ConditionBrowseLeafName": "Skin Ulcer",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14826",
            "ConditionBrowseLeafName": "Skin Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6267",
            "ConditionBrowseLeafName": "Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M25157",
            "ConditionBrowseLeafName": "Diabetes Complications",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6276",
            "ConditionBrowseLeafName": "Diabetic Neuropathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7810",
            "ConditionBrowseLeafName": "Foot Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          }
        ]
      }
    }
  }
}